C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project

Natalie Arnold,Christopher Blaum,Alina Goßling,Fabian J Brunner,Benjamin Bay,Marco M Ferrario,Paolo Brambilla,Giancarlo Cesana,Valerio Leoni,Luigi Palmieri,Chiara Donfrancesco,Teresa Padró,Jonas Andersson,Pekka Jousilahti,Francisco Ojeda,Tanja Zeller,Allan Linneberg,Stefan Söderberg,Licia Iacoviello,Francesco Gianfagna,Susana Sans,Giovanni Veronesi,Barbara Thorand,Annette Peters,Hugh Tunstall-Pedoe,Frank Kee,Veikko Salomaa,Renate B Schnabel,Kari Kuulasmaa,Stefan Blankenberg,Wolfgang Koenig,Christoph Waldeyer

DOI: https://doi.org/10.1093/eurheartj/ehad867

IF: 39.3

2024-01-21

European Heart Journal

Abstract:Recent investigations have suggested an interdependence of lipoprotein(a) [Lp(a)]-related risk for cardiovascular disease with background inflammatory burden. The aim the present analysis was to investigate whether high-sensitive C-reactive protein (hsCRP) modulates the association between Lp(a) and coronary heart disease (CHD) in the general population. Data from 71 678 participants from 8 European prospective population-based cohort studies were used (65 661 without/6017 with established CHD at baseline; median follow-up 9.8/13.8 years, respectively). Fine and Gray competing risk-adjusted models were calculated according to accompanying hsCRP concentration (<2 and ≥2 mg/L). Among CHD-free individuals, increased Lp(a) levels were associated with incident CHD irrespective of hsCRP concentration: fully adjusted sub-distribution hazard ratios [sHRs (95% confidence interval)] for the highest vs. lowest fifth of Lp(a) distribution were 1.45 (1.23–1.72) and 1.48 (1.23–1.78) for a hsCRP group of <2 and ≥2 mg/L, respectively, with no interaction found between these two biomarkers on CHD risk ( P interaction = 0.82). In those with established CHD, similar associations were seen only among individuals with hsCRP ≥ 2 mg/L [1.34 (1.03–1.76)], whereas among participants with a hsCRP concentration <2 mg/L, there was no clear association between Lp(a) and future CHD events [1.29 (0.98–1.71)] (highest vs. lowest fifth, fully adjusted models; P interaction = 0.024). While among CHD-free individuals Lp(a) was significantly associated with incident CHD regardless of hsCRP, in participants with CHD at baseline, Lp(a) was related to recurrent CHD events only in those with residual inflammatory risk. These findings might guide adequate selection of high-risk patients for forthcoming Lp(a)-targeting compounds. C-reactive protein as a possible modifier of lipoprotein(a)-related risk for coronary heart disease in Europe. CHD, coronary heart disease; CI, confidence interval; Lp(a), lipoprotein(a); FU, follow-up; F, fifth; hsCRP, high-sensitive C-reactive protein; sHR, sub-distribution hazard ratio.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The paper primarily investigates whether high-sensitivity C-reactive protein (hsCRP) can modulate the association between lipoprotein(a) [Lp(a)] and the risk of coronary heart disease (CHD). The study utilized data from 71,678 participants from 8 European prospective cohort studies, of which 65,661 participants were free of CHD at baseline, while 6,017 participants had CHD at baseline. The analysis was conducted using the Fine and Gray competing risks regression model, and was stratified by accompanying hsCRP concentrations (<2 and ≥2 mg/L).

The results indicated that in individuals without CHD, elevated levels of Lp(a) were associated with the incidence of new CHD events, regardless of hsCRP concentration. Specifically, compared to the lowest quintile of Lp(a) distribution, the fully adjusted subdistribution hazard ratios (sHR) for the highest quintile were 1.45 (1.23-1.72) and 1.48 (1.23-1.78) for hsCRP groups <2 and ≥2 mg/L, respectively, with no significant interaction effect between the two biomarkers on CHD risk (Pinteraction = 0.82).

However, among participants with CHD at baseline, a similar association was only observed in individuals with hsCRP ≥2 mg/L [compared to the lowest quintile of Lp(a), sHR was 1.34 (1.03-1.76)], while in participants with hsCRP concentrations <2 mg/L, there was no significant association between Lp(a) and future CHD events [sHR was 1.29 (0.98-1.71) for the highest versus lowest quintile, fully adjusted model; Pinteraction = 0.024].

In conclusion, while Lp(a) was significantly associated with the incidence of new CHD events in individuals without CHD, regardless of hsCRP levels, in participants with CHD at baseline, Lp(a) was only associated with recurrent CHD events in individuals with residual inflammatory risk. These findings may guide the selection of high-risk patients for upcoming trials targeting Lp(a).

In summary, the paper aims to study whether hsCRP can modulate the relationship between Lp(a) and CHD risk, finding that this modulatory effect is not evident in individuals without CHD, but in those with existing CHD, hsCRP does influence the relationship between Lp(a) and CHD risk, suggesting that the inflammatory status should be considered when selecting high-risk patients for Lp(a) targeted therapy.